Research programme: CAR T-cell cis-targeted interleukin-2 immunotherapy- Asher Biotherapeutics
Alternative Names: CAR-T cis-targeted IL-2 immunotherapy - Asher Biotherapeutics; Chimeric antigen receptor T-cell cis-targeted interleukin-2 immunotherapyLatest Information Update: 13 Jun 2023
At a glance
- Originator Asher Biotherapeutics
- Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Interleukin 2 replacements; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 14 Apr 2023 Pharmacodynamics and adverse events data from preclinical trial in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 08 Apr 2022 Pharmacodynamics data from preclinical trial in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research
- 01 Apr 2021 Preclinical trials in Cancer in USA (unspecified route) (Asher Biotherapeutics pipeline, April 2021)